Inspire Will Introduce Trials to Online Community Members


By Deborah Borfitz

April 7, 2008 | A prolific builder of online health communities hopes to make introductions between members of those social networking venues and companies who need participants for their clinical trials. The service would alert prospective volunteers to trial opportunities to which they’d be suited by virtue of gender, age, geography, and medical condition.

The matchmaker is McLean, VA-based Inspire (originally ClinicaHealth), which has spent the last three years developing 35 online communities in partnership with non-profit organizations. The anonymous, one-to-one sharing that goes on in these communities provides important “grounding” for suggesting appropriate clinical trials to members, says CEO Brian Loew.

E-mail alerts will go out to the more than 90 percent of community members who choose to receive periodic, health-related communications, says Loew. The messages will indicate the type and general location of trials, as well as any compensation being offered, and ask individuals to consent to being contacted by the research group. “Decision making is in the hands of members. We just set up the environment. If 99.9 percent of a community doesn’t want to do [a particular trial], that’s fine with us.”

Inspire will earn revenues from the new service based on its efforts and not a “per-head bounty,” says Loew. For all business generated via the online communities, Inspire gives back a portion of revenues to its non-profit partners.

“We feel our first responsibility is to members of the community and their privacy, so we give them a lot of control over the process and don’t use their data in any way they have not agreed to,” says Loew. Ultimately, members may be able to specify preferences for receiving alerts about recruiting clinical trials. “We are very emphatic that we are not a substitute for the physician-patient relationship…and [will tell members] to talk to their doctor about clinical trial opportunities.”

Inspire remains in discussions with four top-ten pharmaceutical and two top-ten biotechnology companies about the clinical trial introduction service, says Loew. “We expect to have several customers by the end of the year.” The company has also just begun collaborating with the Center for Information & Study on Clinical Research Participation (CISCRP) to create an online community to educate people who want to learn more about clinical trials.

According to CISCRP President and CEO Diane Simmons, “the social networking opportunity that will be added to www.ciscrp.org is an extension of our public service.” Inspire is “making it possible for people who have been in trials to share their experience and wisdom with those who are considering participation. CISCRP is not involved in recruiting patients for trials, but we believe in education before participation.”

A fair number of companies have tried and failed to make a go of the clinical trial matchmaking business. “The lesson learned [from the failures] is that no one joins a social network if it’s just about clinical trials, and if they join, they’re not going to come back five times a week,” says Loew.

Members of each Inspire community get routine emails about activity on the site. They can also locate “friends” according to an assortment of criteria that might matter to them, like geographic proximity or similarity of condition or caregiver role, and share pictures of themselves if they so choose.

Inspire has demonstrated that it can create “heat maps” showing where members with different diseases are clustered geographically, which Loew says would be “a good tool for [investigative] site location.”

------------------------

This story first appeared in eCliniqua,one of Bio-IT World’s free e-newsletters. Subscribe here.

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1

White Papers & Special Reports

This Bio•IT World Briefing On “Next-Generation Sequencing,” underwritten by GenomeQuest, Inc.,
presents a selection of feature stories, interviews,commentaries, conference reports, and editorials on the emergence, opportunities, and challenges posed by high-throughput sequencing. Covered in this collection: the launch of new platforms from Applied Biosystems and Helicos; new applications of nextgen sequencing; the rise of personal genomics; and informatics solutions to vexing problem of managing the vast volumes of next-gen data. Download now



SGI's Meeting Today’s Computational Needs for Science

The quest to better understand disease mechanisms and find new treatments is driven by new laboratory technologies and ever-more sophisticated modeling and simulation efforts. As such, life sciences R&D investigations increasingly are relying on more powerful computing resources. The challenge is how to accommodate the broad mix of applications.

Addressing this issue, this paper produced by the Bio-IT World Custom Publishing Group discusses a new SGI Hybrid Computing Environment approach. It optimally uses shared memory systems, multi-processor clusters, and FPGAs to accelerate computational workflows.



sgi_protm

SGI's Supercharging Proteomics Discovery

The deeper study of proteins and their interactions can reveal scientific information once considered nearly untouchable to scientists and researchers. Today, unprecedented advancements in computing power are enabling the creation of mounds of proteomic based data along with the accompanying bottlenecks data can create.

Rather than just “simplify the experiment” to fit the computational resources an alternative is now available with the SGI Proteomics Appliance. This complimentary white paper, produced by the Bio-IT World Custom Publishing Group, looks at ways to use the Proteomic Appliance to handle the most intensive proteomics computing tasks facing science today.



Life Science Webcasts & Podcasts

Trade Commission of Spain

Spain’s Emerging Biotech Revolution

The biotechnology sector is growing 10 percent faster in Spain than it is in the U.S. Driven by a culture, government and private sector that are open-minded and optimistic, Spain-based companies are emerging as leaders in this dynamic field. Discover how your business can capitalize on creative solutions from Spain-based enterprises by learning about:

  • Trends and factors driving the growth of Spain’s biotechnology sector.
  • The Spanish government’s aggressive policies and incentive programs for biotechnology research.
  • Biotechnology spin-offs, bio-clusters and new research centers in Spain that are combining entrepreneurial spirit with larger-than-ever resources.
  • The strength of Spain’s biomedicine community, and how U.S. pharmaceutical companies are capitalizing on it.

Download Now


More Podcasts

Job Openings

Friedrich Miescher Institute for Biomedical Research - Part of the Novartis Research Foundation
Basel, Switzerland is looking for a Head of IT Systems & Infrastructure. You will manage a cutting-edge core server and network infrastructure, comprising Linux and Solaris, as well as a robust Windows and Macintosh environment. We look forward to receiving your application: [email protected]. click for more information

Lilly Singapore Center for Drug Discovery (LSCDD) - Associate Director of Informatics
Lead and mentor a strong team for the Bioinformatics group at the Integrative Computational Sciences (ICS) department at LSCDD towards the development of novel algorithms, data analysis methods and software tools for drug discovery. Work closely with the Software Engineering group at ICS, and collaborate with the Discovery IT organization in Europe and USA. For additional information, or to apply visit: LSCDD

Related Resources & Products

Adaptive Clinical Trials: Innovation in Trial Design, Management, and Analysis
Adaptive Clinical Trials: Innovation in Trial Design, Management, and Analysis
Adaptive Clinical Trials
Imaging in Clinical Trials 2008
Imaging in Clinical Trials 2008




For reprints and/or copyright permission, please contact RMS, 1808 Colonial Village Lane, Lancaster, PA;

(717) 399-1900 ext 100 or via email to [email protected].